pharmaphorum
NOVEMBER 16, 2021
An artificial intelligence algorithm developed by GE Healthcare that helps with the placement of endotracheal tubes (ETTs) has been approved by the FDA. The new tool – part of GE’s Critical Care Suite 2.0 – helps bedside staff and radiologists assess patients before intubation – for example prior to ventilation in patients with critical COVID-19 – and make sure their ETTs are positioned correctly.
Pharma Times
NOVEMBER 15, 2021
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Outsourcing Pharma
NOVEMBER 16, 2021
CRISPR Therapeutics and ViaCyte, Inc. have received the green light from Health Canada for their Clinical Trial Application for VCTX210: an allogeneic, gene-edited, immune-evasive, stem cell-derived therapy for the treatment of type 1 diabetes (T1D).
Drug Patent Watch
NOVEMBER 14, 2021
Annual Drug Patent Expirations for AMTURNIDE Amturnide is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug. This drug has one…. The post New patent expiration for Novartis drug AMTURNIDE appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
NOVEMBER 16, 2021
Amazon’s push into the provision of remote healthcare services has been rewarded with a top-tier corporate client – the Hilton hotel chain. The deal – first reported by Reuters – involves the Amazon Care platform, which includes remote, online consultations with clinicians, as well as home visits in some areas. It provides primary and preventive care, ongoing support for chronic conditions, and referrals to secondary and tertiary care.
Pharma Times
NOVEMBER 18, 2021
The UKHSA have said that deferring the vaccine dose could help to reduce even further the small risk of heart inflammation following vaccination
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
NOVEMBER 16, 2021
The pact between the drug firm and the group is aimed at giving equitable access to treatments and vaccines for people in disadvantaged parts of the world.
pharmaphorum
NOVEMBER 16, 2021
Moderna is already riding high on the strength of its mRNA-based COVID-19 vaccine, but the broader potential of its technology has been shown in a new AstraZeneca-partnered candidate for heart failure. At the American Heart Association (AHA) congress, the two partners presented results from the phase 2a EPICCURE trial that showed that injecting their AZD8601 candidate directly into the heart muscle of patients undergoing coronary artery bypass graft (CABG) surgery seemed to improve heart functio
Pharma Times
NOVEMBER 16, 2021
The data was obtained by a Freedom of Information request, according to The Independent
NY Times
NOVEMBER 16, 2021
The antiviral drugs have helped inspire hope among senior administration officials that the United States will be able to curb the devastating toll from the Delta variant.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Channels
NOVEMBER 16, 2021
In Consolidation and Preferred Pharmacy Networks in 2022’s Medicare Part D Plans , I highlighted how those networks have hijacked the world of stand-alone Medicare Part D prescription drug plans (PDP) and become a major presence in Medicare Advantage prescription drug (MA-PD) plans. Today, I examine the largest retail chains’ participation in the 21 major 2022 Part D preferred networks that the eight largest plan sponsors will offer.
pharmaphorum
NOVEMBER 19, 2021
US company Respira Labs has developed a device worn on the chest that uses tiny speakers and microphones to project sound into the lungs and listen for signals that could indicate serious lung diseases. The Sylvee wearable uses an artificial intelligence (AI) algorithm to interpret sounds that may indicate trapped air in the lungs, which can be a sign of ill health, using acoustic resonance – similar to the way an ultrasound machine creates visual images.
Pharma Times
NOVEMBER 17, 2021
This deal will see more patients having access to treatment which could prevent 21,700 strokes and 5,400 deaths
NY Times
NOVEMBER 19, 2021
If the C.D.C. agrees, adults who received a second shot of the Pfizer or Moderna vaccine at least six months ago could be eligible by this weekend.
Drug Channels
NOVEMBER 19, 2021
Today’s guest post comes from Carolyn Zele, Senior Manager of Solution Enablement at MMIT. Carolyn describes how oncology pathways were developed to help standardize treatment and ensure quality care. She argues, however, that these pathways often shut manufacturers out of the market. Click here to learn more about MMIT's Pulse Analytics solution , which provides insight into payer- and pathway-driven barriers to access.
pharmaphorum
NOVEMBER 15, 2021
Patients with sickle cell disease are facing racism in the NHS that is putting their lives a risk, claims a new report. . The All-Party Parliamentary Group (APPG) document – entitled No One’s Listening and partnered with the Sickle Cell Society – found “serious care failings” in acute services and evidence of attitudes underpinned by racism in the care of people with SCD, a red blood cell disorder that mainly affects black people.
Pharma Times
NOVEMBER 15, 2021
Epilepsy affects over 600,000 people in the UK, which is approximately one in every 100 people
NY Times
NOVEMBER 16, 2021
The treatment, Paxlovid, is the second antiviral pill to show effectiveness in treating Covid, and works differently from the first.
Outsourcing Pharma
NOVEMBER 16, 2021
According to the pharma firm, Saphnelo (anifrolumab) combined with standard therapy resulted in reduction of systemic lupus erythematosus disease activity.
pharmaphorum
NOVEMBER 15, 2021
Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms in a clinical trial that relied entirely on remote monitoring of symptoms using a smartphone app. The real-world CHIEF-HF study is said to be the first fully “decentralised, mobile, indication-seeking clinical study” with no need for patients to visit clinic, according to J&J’s pharma division Janssen.
Pharma Times
NOVEMBER 19, 2021
Vumerity is a next-generation oral fumarate treatment for adults with relapsing-remitting multiple sclerosis
NY Times
NOVEMBER 17, 2021
The Biden administration will spend billions of dollars on a new plan to combat the pandemic, investing in antiviral pills, rapid tests and manufacturing.
Outsourcing Pharma
NOVEMBER 17, 2021
According to data released by the company, the majority of study professionals plan to run agile or hybrid trials over the course of the next 12 months.
pharmaphorum
NOVEMBER 16, 2021
Biogen’s chief medical officer Al Sandrock has announced he will retire at the end of the year, ending a 23-year career at the biotech. The architect of many of Biogen’s biggest-selling drugs, Sandrock is bowing out as Biogen is still struggling with the rollout of its controversial new Alzheimer’s disease therapy Aduhelm (aducanumab).
Pharma Times
NOVEMBER 19, 2021
Eligible adult patients with primary or secondary myelofibrosis will now be able to access the treatment on the NHS
NY Times
NOVEMBER 16, 2021
Regulators are set to clear extra doses of Pfizer-BioNTech’s vaccine as soon as Thursday, after states began expanding eligibility on their own.
Drug Channels
NOVEMBER 18, 2021
In my previous post , I highlighted the largest pharmacy chains that will participate in the 2022 Medicare Part D prescription drug plans (PDP). Today, I examine how smaller pharmacies will participate as preferred cost sharing pharmacies via the pharmacy services administrative organizations (PSAOs) that represent them in negotiations with plans. As you will see here, the largest PSAOs are increasingly rejecting preferred networks.
pharmaphorum
NOVEMBER 18, 2021
Its vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new modalities and searching for valuable collaborators, according to the company’s senior VP of global drug discovery Karin Conde-Knape. She discusses which therapeutic areas the company is gaining momentum in and how it aims to build its presence within these areas through external partnerships, in a session at the recent BIO-Europe with pharmaphorum’s founder Paul Tunnah.
Pharma Times
NOVEMBER 16, 2021
Voluntary license agreement will allow generic versions of pill to be manufactured
Outsourcing Pharma
NOVEMBER 15, 2021
The pharma company has completed enrollment of amyotrophic lateral sclerosis patients in its study investigating drugs like verdiperstat, an oral treatment.
NY Times
NOVEMBER 19, 2021
The move adds more than 2.8 million young people to those eligible for a shot.
pharmaphorum
NOVEMBER 17, 2021
Armed with impressive new data for its oral antiviral Paxlovid, Pfizer has filed for emergency use authorisation as a COVID-19 treatment in the US – and signed a deal to allow other manufacturers to make it in some lower-income countries. Paxlovid – based on new protease inhibitor PF-07321332 and HIV drug ritonavir – was found to reduce the risk of hospitalisations and death in mild to moderate COVID-19 patients by 89% compared to placebo when given in the early stages of infection.
Pharma Times
NOVEMBER 16, 2021
Treatment authorised for use in adults with COVID-19 who are at high-risk of progressing to severe disease
Drug Patent Watch
NOVEMBER 19, 2021
Annual Drug Patent Expirations for RAYALDEE Rayaldee is a drug marketed by Eirgen and is included in one NDA. It is available from one supplier. There are thirteen patents protecting…. The post New patent for Eirgen drug RAYALDEE appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
NOVEMBER 19, 2021
With prices rising at their fastest rate in decades, people in retirement or approaching it should take extra care to protect their savings.
Expert insights. Personalized for you.
145 
Let's personalize your content